# Wall Street's Wild Stock Picks: October Edition Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-10-03T23:34:24.700Z Source: https://newsyai.com/edition/c06a32a5-f1ab-472c-94d4-43cc7f17fcb2 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 3, 2026 Edition**[[1]](https://www.findmymoat.com/short-interest) Back at it, you beautiful degenerates. Markets remain a glorious clusterfuck—AI hype propping the Nasdaq while the Dow sits flatter than day-old piss and crude oil swings like a drunk on a seesaw. I dug into the latest short-interest scans (Sep 25 settlement data dominating the tape, with fresh Oct updates confirming the chaos) for three *brand-new* names where the bears are loading up like it's Black Friday on pessimism, and the bulls are screaming "squeeze me harder." No repeats of HTZ/PLCE/QUBT/GRPN/SOUN/SERV/LCID/METC/RXRX/ONDS/etc.—just raw, divided chaos with shorts north of 30-90% yelling "prove me wrong, bitch." Here's the latest holy trinity of "who the actual fuck knows?" ### 1. UAA (Under Armour): The Athletic Wear Has-Been with a Turnaround Fetish **The Bull Case (We're the Underdog Brand That Won't Die—Revival Incoming):** Bulls see a legendary name with massive brand equity, potential for product innovation, omnichannel fixes, and a "consumer comeback" narrative amid athletic wear demand. Shorts are stacked to the fucking gills (~95% of float in recent scans—yes, *ninety-five percent*), but any earnings beat, celebrity endorsement pop, or macro retail resilience could trigger a violent short squeeze. "The brand's iconic, the balance sheet's stabilizing, and we're scaling the future of performance gear" is the cope—watch revenue ramp while shorts get left in the dust.[[2]](https://www.tipranks.com/screener/most-shorted-stocks) **The Bear Case (Dying Brand in a Nike/Lululemon Apocalypse):** Reality slaps: Brutal competition from bigger, faster rivals; margin pressure; inventory issues; and a business model that screams "declining relevance in a hype-driven market." Insane short interest reflects the market's verdict—this thing has been promising a glorious athletic renaissance forever while fighting for shelf space and fighting off dilution or worse. One missed quarter, fashion miss, or consumer slowdown and it's pain city. Under Armour? More like under pressure.[[2]](https://www.tipranks.com/screener/most-shorted-stocks) **My First-Principles Breakdown:** Strip it to atoms: Apparel wins on brand loyalty, margin discipline, and trend alignment—not just legacy logos. UAA has name recognition and turnaround scars that could breed focus, but "revival story" assumes flawless execution against deeper-pocketed, trendier competitors and real-world consumer shifts that don't lie. Shorts correctly price in structural headwinds in a hyper-competitive space; bulls correctly price in asymmetric upside if the brand clicks again. Classic high-vol binary—entertaining volatility, not a "set it and forget it" core holding. ### 2. IBRX (ImmunityBio): The Biotech Moonshot with Pipeline Dreams **The Bull Case (We're the Next-Gen Immuno-Oncology Play—Breakthroughs Ahead):** Bulls hype the company's oncology and infectious disease pipeline, potential for novel therapies, partnerships, and "unmet medical need" tailwinds. Shorts are piled on (~40%+ of float), but any positive trial data, regulatory win, or funding pop could spark a squeeze. "We've got the science and we're adapting to the future of medicine" is the mantra—advance the platform and watch shorts eat their lab coats.[[3]](https://www.chartmill.com/stock/markets/usa/screener/most-shorted-stocks) **The Bear Case (Cash-Burning Spec with Long Timelines and Regulatory Roulette):** Reality bites: Heavy cash burn, insanely long timelines to real revenue, competition from bigger biotechs, and a model that screams "dilution or failure ahead." High shorts aren't random—they're the market saying "this growth story is speculative as hell." One bad trial readout, macro funding crunch, or execution miss and it's more dilution or worse. ImmunityBio? More like immunity to profits risk.[[4]](https://www.strasmore.com/blog/most-shorted-stocks) **My First-Principles Breakdown:** Fundamentally, biotech lives or dies on clinical validation, capital efficiency, and differentiation. IBRX has a recognizable platform and potential for leaner ops or big wins, but "pipeline success" requires consistent data and low churn in a hyper-competitive, regulation-driven space. Shorts flag structural funding and timeline headwinds; bulls flag optionality if therapies deliver. High-risk biotech bet with squeeze lottery potential—trade the narrative, size like your portfolio depends on it (or don't). ### 3. CLSK (CleanSpark): The Bitcoin Miner/Energy Hybrid That's Volatile as Hell **The Bull Case (We're the Efficient Crypto Infrastructure Play—Bitcoin Boom Meets Energy Edge):** Bulls see a miner with operational efficiency, potential expansion into energy plays, and "digital asset + renewables" tailwinds. Shorts are aggressive (~40%+ in scans), setting up a moonshot on any Bitcoin rally, hash rate growth, or energy deal. "We've got the scale and we're the future of sustainable mining" is the rally cry—monetize the ops and shorts get left in the blockchain dust.[[3]](https://www.chartmill.com/stock/markets/usa/screener/most-shorted-stocks) **The Bear Case (Speculative Crypto Bet with Energy Headwinds and Dilution Risks):** Reality: Massive volatility tied to Bitcoin prices, high capex needs, competition from bigger miners, and a valuation that assumes perfection in a cyclical industry. Shorts see through the hype—most of this is still speculative bets on crypto translating to sustainable profits that could flop. One crypto winter, energy cost spike, or dilution wave and the dream evaporates. CleanSpark? More like clean miss.[[3]](https://www.chartmill.com/stock/markets/usa/screener/most-shorted-stocks) **My First-Principles Breakdown:** At core, crypto mining is a probability game of energy costs, hash rate efficiency, and capital—Bitcoin price and operational discipline matter more than hype. CLSK has a differentiated angle and early momentum, but "scaling sustainably" assumes the edge survives real-world volatility and brutal competition. Shorts correctly flag the binary commodity and funding risks; bulls correctly flag the transformative upside if crypto meaningfully bends the compute/energy curve. High-volatility speculation—lottery ticket with real infrastructure intrigue. **Bottom Line (No Crystal Ball, Just Brutal Logic):** These three capture the current divided vibe: athletic apparel revival gamble, biotech pipeline bet, and crypto/energy moonshot. The common thread? Sky-high skepticism via shorts (some absurdly so), but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don't), and remember: this is entertainment with numbers. Your move, degenerates. **Sources for the terminally curious (verify this shit yourself):** Recent short-interest trackers and screens (e.g., FindMyMoat, TipRanks, ChartMill, Benzinga, Tapeboard) highlighting elevated levels in UAA, IBRX, and CLSK; market commentary on the underlying sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don't cry when it goes tits up.